Myofibre Density Reveals a Critical Threshold Around Age 6 in Steroid‐Naïve Duchenne Muscular Dystrophy: A Retrospective Observational Study
Authors:
Open Access
- 18 March 2026
- journal article
- research article
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 52 (2) , e70068
Abstract
Aims: In Duchenne muscular dystrophy (DMD), robust histological markers for assessing early disease progression remain elusive. We defined myofibre density ( MFD ) as the count of myofibres per square millimetre, which, in our preliminary survey of DMD muscle biopsies, steeply declined with age (Spearman's ρ : −0.85). We aimed to characterise age‐dependent MFD dynamics in early‐stage DMD. Methods: We retrospectively assessed 46 archival muscle‐biopsy slides (steroid‐naïve; collected > 40 years ago) using semi‐quantitative image analysis with digital restoration. MFD and classical histological variables were quantified. Age– MFD dynamics were modelled with segmented regression and validated using weakly informative Bayesian modelling. The primary measure was the MFD age‐breakpoint. Secondary measures included breakpoint‐detection power, age‐predictive MFD cut‐offs and behaviour of conventional variables across breakpoint‐defined age bands. Results: After quality and age‐distribution screening, 35 slides (age 1–11 years) were analysed. Segmented regression identified a breakpoint at 6.25 years (95% confidence interval [CI]: 5.08–7.42); after which MFD plateaued at lower levels. Bayesian posterior estimate was 6.37 years (95% credible interval: 5.24–7.66). A 10,000‐run Monte Carlo simulation ( n = 35) showed approximately 80% power to recapture the breakpoint within ±1.25 years. MFD cut‐offs > 596 and < 426 fibres/mm 2 corresponded to 80% and 20% probabilities of age < 6.25 years. Between the early (< 5 years) and late (≥ 7.5 years) age bands defined by the breakpoint–CI limits, myofibre‐size parameters, myofibre area and fat replacement shifted significantly. Conclusions: MFD , a simple metric, reveals a previously unrecognised phase of rapid myofibre loss lasting up to around age 6 in early‐stage DMD.Keywords
This publication has 59 references indexed in Scilit:
- Choice of compound, dosage, and management of side effects for long-term corticosteroid treatment in Duchenne muscular dystrophy: Guidelines from the Neuromuscular Commission of the French Society of Pediatric NeurologyArchives de Pédiatrie, 2024
- Predicting histopathological features of aggressiveness in lung cancer using CT radiomics: a systematic reviewClinical Radiology, 2024
- Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular DystrophyJAMA Neurology, 2022
- Biomarker Qualification at the European Medicines Agency: A Review of Biomarker Qualification Procedures From 2008 to 2020Clinical Pharmacology & Therapeutics, 2022
- Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular DystrophyJAMA Neurology, 2020
- Corticosteroids for the treatment of Duchenne muscular dystrophyCochrane Database of Systematic Reviews, 2016
- Eteplirsen for the treatment of Duchenne muscular dystrophyAnnals of Neurology, 2013
- THE 6‐minute walk test and other endpoints in Duchenne muscular dystrophy: Longitudinal natural history observations over 48 weeks from a multicenter studyMuscle & Nerve, 2013
- Estimating regression models with unknown break‐pointsStatistics in Medicine, 2003
- Clinical investigation in duchenne dystrophy: 2. Determination of the “power” of therapeutic trials based on the natural historyMuscle & Nerve, 1983